New York  London  GMT  Tokyo  Singapore 
TECHNOLOGY: MARKET OPINIONS
November 2nd, 2009 - HGSI - Human Genome Sciences, Inc. - There was a predictable investor response after results of late-stage clinical trials on Benlysta paved the way for the first new lupus treatment for a half decade. Shares in the company surged to a high of $26.21 but are now pulling back to show a ...
Author: Andrew Wilkinson
Page 2 of 42«12345»...Last »
F = Forex S = Stock C = Commodities E = Economy * Headline Only





Theme By: WordPress Theme Shop